The pharmaceutical company, which is developing treatments for ear disorders, has now secured more than $143m in total from backers including Novo.
US-based biopharmaceutical company Otonomy has raised $49m from an oversubscribed series D round backed by investors including Novo Ventures, the corporate venturing arm of healthcare company Novo.
Novo was joined in the round by additional existing backers including OrbiMed Advisors, TPG Biotech, Avalon Ventures, Domain Associates, RiverVest Venture Partners, Aperture Venture Partners, and Osage University Partners.
Jennison Associates, Perceptive Advisors, Federated Kaufmann Funds, some private investment funds advised by Clough Capital Partners, Ally Bridge Group and some undisclosed institutional investors…
